The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells.

MLA

Simioni, Carolina, et al. “The Novel Dual PI3K/MTOR Inhibitor NVP-BGT226 Displays Cytotoxic Activity in Both Normoxic and Hypoxic Hepatocarcinoma Cells.” Oncotarget, vol. 6, no. 19, July 2015, pp. 17147–60. EBSCOhost, https://doi.org/10.18632/oncotarget.3940.

APA

Simioni, C., Cani, A., Martelli, A. M., Zauli, G., Alameen, A. A. M., Ultimo, S., Tabellini, G., McCubrey, J. A., Capitani, S., & Neri, L. M. (2015). The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget, 6(19), 17147–17160. https://doi.org/10.18632/oncotarget.3940

Chicago

Simioni, Carolina, Alice Cani, Alberto M Martelli, Giorgio Zauli, Ayman A M Alameen, Simona Ultimo, Giovanna Tabellini, James A McCubrey, Silvano Capitani, and Luca M Neri. 2015. “The Novel Dual PI3K/MTOR Inhibitor NVP-BGT226 Displays Cytotoxic Activity in Both Normoxic and Hypoxic Hepatocarcinoma Cells.” Oncotarget 6 (19): 17147–60. doi:10.18632/oncotarget.3940.